The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

PURPOSE: Marginal zone lymphoma (MZL) is an uncommon non–Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Opat, Stephen, Tedeschi, Alessandra, Linton, Kim, McKay, Pamela, Hu, Bei, Chan, Henry, Jin, Jie, Sobieraj-Teague, Magdalena, Zinzani, Pier Luigi, Coleman, Morton, Thieblemont, Catherine, Browett, Peter, Ke, Xiaoyan, Sun, Mingyuan, Marcus, Robert, Portell, Craig A., Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Mapp, Sally, Ho, Shir-Jing, Talaulikar, Dipti, Zhou, Ke-Shu, Co, Melannie, Li, Xiaotong, Zhou, Wenxiao, Cappellini, Massimo, Tankersley, Chris, Huang, Jane, Trotman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401507/
https://www.ncbi.nlm.nih.gov/pubmed/34526366
http://dx.doi.org/10.1158/1078-0432.CCR-21-1704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401507/
https://www.ncbi.nlm.nih.gov/pubmed/34526366
http://dx.doi.org/10.1158/1078-0432.CCR-21-1704

Ejemplares similares